{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:13:09Z","timestamp":1774422789915,"version":"3.50.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T00:00:00Z","timestamp":1539734400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11914-018-0483-3","type":"journal-article","created":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T04:33:18Z","timestamp":1539750798000},"page":"674-692","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Gonadal Hormones in the Pathogenesis and Treatment of Bone Health in Patients with Chronic Kidney Disease: a Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"16","author":[{"given":"Jasna","family":"Aleksova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander J.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"McLachlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances","family":"Milat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter R.","family":"Ebeling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,17]]},"reference":[{"key":"483_CR1","unstructured":"ABS, Canberra. Australian Bureau of Statistics 2013. Australian Health Survey: biomedical results for chronic diseases, 2011\u201312 05\/08\/2013 [cited 2016. Available from: \n                      http:\/\/www.abs.gov.au\/ausstats\/abs@.nsf\/Lookup\/4364.0.55.005main+features12011-12\n                      \n                    ."},{"issue":"23","key":"483_CR2","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1001\/jama.288.23.3014","volume":"288","author":"AM Ball","year":"2002","unstructured":"Ball AM, Gillen DL, Sherrard D, Weiss NS, Emerson SS, Seliger SL, et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA. 2002;288(23):3014\u20138.","journal-title":"JAMA"},{"issue":"1","key":"483_CR3","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1046\/j.1523-1755.2000.00178.x","volume":"58","author":"AM Alem","year":"2000","unstructured":"Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58(1):396\u20139.","journal-title":"Kidney Int"},{"issue":"1","key":"483_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","volume":"92","author":"M Ketteler","year":"2017","unstructured":"Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what\u2019s changed and why it matters. Kidney Int. 2017;92(1):26\u201336.","journal-title":"Kidney Int"},{"issue":"8","key":"483_CR5","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.2215\/CJN.06300613","volume":"8","author":"KE Ensrud","year":"2013","unstructured":"Ensrud KE. Fracture risk in CKD. Clin J Am Soc Nephrol. 2013;8(8):1282\u20133.","journal-title":"Clin J Am Soc Nephrol"},{"key":"483_CR6","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/bonekey.2014.37","volume":"3","author":"PD Miller","year":"2014","unstructured":"Miller PD. Chronic kidney disease and osteoporosis: evaluation and management. BoneKEy reports. 2014;3:542.","journal-title":"BoneKEy reports"},{"issue":"7","key":"483_CR7","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1359\/JBMR.050304","volume":"20","author":"O Johnell","year":"2005","unstructured":"Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20(7):1185\u201394.","journal-title":"J Bone Miner Res"},{"issue":"9","key":"483_CR8","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1007\/s00198-006-0135-9","volume":"17","author":"JA Pasco","year":"2006","unstructured":"Pasco JA, Seeman E, Henry MJ, Merriman EN, Nicholson GC, Kotowicz MA. The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int. 2006;17(9):1404\u20139.","journal-title":"Osteoporos Int"},{"issue":"10","key":"483_CR9","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1359\/JBMR.050609","volume":"20","author":"E Sornay-Rendu","year":"2005","unstructured":"Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res. 2005;20(10):1813\u20139.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"483_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1359\/jbmr.061014","volume":"22","author":"SK Jassal","year":"2007","unstructured":"Jassal SK, von Muhlen D, Barrett-Connor E. Measures of renal function, BMD, bone loss, and osteoporotic fracture in older adults: the Rancho Bernardo study. J Bone Miner Res. 2007;22(2):203\u201310.","journal-title":"J Bone Miner Res"},{"issue":"7","key":"483_CR11","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.2215\/CJN.12871211","volume":"7","author":"RH Yenchek","year":"2012","unstructured":"Yenchek RH, Ix JH, Shlipak MG, Bauer DC, Rianon NJ, Kritchevsky SB, et al. Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol. 2012;7(7):1130\u20136.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"483_CR12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.2215\/CJN.06040614","volume":"10","author":"KL Naylor","year":"2015","unstructured":"Naylor KL, Garg AX, Zou G, Langsetmo L, Leslie WD, Fraser LA, et al. Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol. 2015;10(4):646\u201353.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"483_CR13","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/jbmr.2406","volume":"30","author":"SL West","year":"2015","unstructured":"West SL, Lok CE, Langsetmo L, Cheung AM, Szabo E, Pearce D, et al. Bone mineral density predicts fractures in chronic kidney disease. J Bone Miner Res. 2015;30(5):913\u20139.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"483_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/ndt\/gfr317","volume":"27","author":"S Iimori","year":"2012","unstructured":"Iimori S, Mori Y, Akita W, Kuyama T, Takada S, Asai T, et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients--a single-center cohort study. Nephrol Dial Transplant. 2012;27(1):345\u201351.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"483_CR15","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1681\/ASN.2009121208","volume":"21","author":"TL Nickolas","year":"2010","unstructured":"Nickolas TL, Stein E, Cohen A, Thomas V, Staron RB, McMahon DJ, et al. Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol. 2010;21(8):1371\u201380.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"483_CR16","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1002\/jbmr.1916","volume":"28","author":"TL Nickolas","year":"2013","unstructured":"Nickolas TL, Stein EM, Dworakowski E, Nishiyama KK, Komandah-Kosseh M, Zhang CA, et al. Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res. 2013;28(8):1811\u201320.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"483_CR17","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00198-011-1781-0","volume":"23","author":"SA Jamal","year":"2012","unstructured":"Jamal SA, West SL, Miller PD. Fracture risk assessment in patients with chronic kidney disease. Osteoporos Int. 2012;23(4):1191\u20138.","journal-title":"Osteoporos Int"},{"issue":"1","key":"483_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/joim.12361","volume":"278","author":"SL West","year":"2015","unstructured":"West SL, Patel P, Jamal SA. How to predict and treat increased fracture risk in chronic kidney disease. J Intern Med. 2015;278(1):19\u201328.","journal-title":"J Intern Med"},{"issue":"12","key":"483_CR19","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1359\/JBMR.050817","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005;20(12):2105\u201315.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"483_CR20","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1359\/jbmr.070112","volume":"22","author":"SA Jamal","year":"2007","unstructured":"Jamal SA, Bauer DC, Ensrud KE, Cauley JA, Hochberg M, Ishani A, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res. 2007;22(4):503\u20138.","journal-title":"J Bone Miner Res"},{"issue":"8","key":"483_CR21","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756\u201365.","journal-title":"N Engl J Med"},{"issue":"8","key":"483_CR22","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jbmr.403","volume":"26","author":"SA Jamal","year":"2011","unstructured":"Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26(8):1829\u201335.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"483_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","volume":"18","author":"PD Miller","year":"2007","unstructured":"Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int. 2007;18(1):59\u201368.","journal-title":"Osteoporos Int"},{"issue":"10","key":"483_CR24","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1210\/jc.2006-0173","volume":"91","author":"HA Fink","year":"2006","unstructured":"Fink HA, Ewing SK, Ensrud KE, Barrett-Connor E, Taylor BC, Cauley JA, et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab. 2006;91(10):3908\u201315.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"483_CR25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/syn.21922","volume":"23","author":"L Zhu","year":"2016","unstructured":"\u2022 Zhu L, Jiang X, Sun Y, Shu W. Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis of randomized controlled trials. Menopause (New York, NY). 2016;23(4):461\u201370 A comprehensive meta-analysis showing hormone replacement in women (without CKD) is associated with reduced total, hip and vertebral fractures.","journal-title":"Menopause (New York, NY)"},{"key":"483_CR26","doi-asserted-by":"crossref","unstructured":"Bone fractures after menopause. Hum Reprod Update 2010;16(6):761\u201373.","DOI":"10.1093\/humupd\/dmq008"},{"issue":"9","key":"483_CR27","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1210\/jc.2009-0206","volume":"94","author":"ES LeBlanc","year":"2009","unstructured":"LeBlanc ES, Nielson CM, Marshall LM, Lapidus JA, Barrett-Connor E, Ensrud KE, et al. The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J Clin Endocrinol Metab. 2009;94(9):3337\u201346.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"483_CR28","first-page":"2787","volume":"86","author":"SA Stoch","year":"2001","unstructured":"Stoch SA, Parker RA, Chen L, Bubley G, Ko YJ, Vincelette A, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 2001;86(6):2787\u201391.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"483_CR29","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.tem.2012.03.008","volume":"23","author":"S Khosla","year":"2012","unstructured":"Khosla S, Oursler MJ, Monroe DG. Estrogen and the skeleton. Trends Endocrinol Metab. 2012;23(11):576\u201381.","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"483_CR30","first-page":"143","volume":"2","author":"GE Krassas","year":"2001","unstructured":"Krassas GE, Papadopoulou P. Oestrogen action on bone cells. J Musculoskelet Neuronal Interact. 2001;2(2):143\u201351.","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"4","key":"483_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00223-001-1044-8","volume":"69","author":"S Khosla","year":"2001","unstructured":"Khosla S, Melton LJ 3rd, Riggs BL. Estrogens and bone health in men. Calcif Tissue Int. 2001;69(4):189\u201392.","journal-title":"Calcif Tissue Int"},{"issue":"9","key":"483_CR32","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1210\/jc.2009-2635","volume":"95","author":"JA Cauley","year":"2010","unstructured":"Cauley JA, Ewing SK, Taylor BC, Fink HA, Ensrud KE, Bauer DC, et al. Sex steroid hormones in older men: longitudinal associations with 4.5-year change in hip bone mineral density--the osteoporotic fractures in men study. J Clin Endocrinol Metab. 2010;95(9):4314\u201323.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"483_CR33","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1210\/jcem.86.8.7736","volume":"86","author":"S Khosla","year":"2001","unstructured":"Khosla S, Melton LJ, Atkinson EJ, O'Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab. 2001;86(8):3555\u201361.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"483_CR34","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.1210\/jc.2003-030736","volume":"88","author":"L Gennari","year":"2003","unstructured":"Gennari L, Merlotti D, Martini G, Gonnelli S, Franci B, Campagna S, et al. Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J Clin Endocrinol Metab. 2003;88(11):5327\u201333.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"483_CR35","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/j.1365-2265.2010.03868.x","volume":"73","author":"PM Crofton","year":"2010","unstructured":"Crofton PM, Evans N, Bath LE, Warner P, Whitehead TJ, Critchley HO, et al. Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. Clin Endocrinol. 2010;73(6):707\u201314.","journal-title":"Clin Endocrinol"},{"key":"483_CR36","doi-asserted-by":"crossref","unstructured":"Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen\/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA 1996;276(17):1389\u201396","DOI":"10.1001\/jama.276.17.1389"},{"issue":"13","key":"483_CR37","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","volume":"290","author":"JA Cauley","year":"2003","unstructured":"Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women\u2019s Health Initiative randomized trial. JAMA. 2003;290(13):1729\u201338.","journal-title":"JAMA"},{"issue":"3","key":"483_CR38","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1172\/JCI84137","volume":"126","author":"JS Finkelstein","year":"2016","unstructured":"\u2022 Finkelstein JS, Lee H, Leder BZ, Burnett-Bowie SA, Goldstein DW, Hahn CW, et al. Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. J Clin Invest. 2016;126(3):1114\u201325 Shows that estrogen is the primary regulator of bone homeostasis in men and decline in testosterone and estrogen (via aromatisation) cause a reduction in BMD in the male skeleton.","journal-title":"J Clin Invest"},{"issue":"Suppl","key":"483_CR39","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/S0025-6196(19)30648-2","volume":"75","author":"JL Tenover","year":"2000","unstructured":"Tenover JL. Experience with testosterone replacement in the elderly. Mayo Clin Proc. 2000;75(Suppl):S77\u201381 discussion S2.","journal-title":"Mayo Clin Proc"},{"key":"483_CR40","unstructured":"\u2022 Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2018:jc.2018\u201300229-jc.2018. Evidence based guidelines from the US Endocrine Society advocating testosterone replacement in hypogonadal men (without CKD) for bone health."},{"issue":"18","key":"483_CR41","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1503\/cmaj.150033","volume":"187","author":"A Morales","year":"2015","unstructured":"Morales A, Bebb RA, Manjoo P, Assimakopoulos P, Axler J, Collier C, et al. Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline. CMAJ. 2015;187(18):1369\u201377.","journal-title":"CMAJ"},{"issue":"5","key":"483_CR42","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/humrep\/dew027","volume":"31","author":"L Webber","year":"2016","unstructured":"Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, et al. ESHRE guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926\u201337.","journal-title":"Hum Reprod"},{"issue":"972","key":"483_CR43","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1136\/pgmj.2006.045963","volume":"82","author":"F Albaaj","year":"2006","unstructured":"Albaaj F, Sivalingham M, Haynes P, McKinnon G, Foley RN, Waldek S, et al. Prevalence of hypogonadism in male patients with renal failure. Postgrad Med J. 2006;82(972):693\u20136.","journal-title":"Postgrad Med J"},{"issue":"3","key":"483_CR44","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.ajkd.2014.03.010","volume":"64","author":"KK Khurana","year":"2014","unstructured":"Khurana KK, Navaneethan SD, Arrigain S, Schold JD, Nally JV, Shoskes DA. Serum testosterone levels and mortality in men with CKD stages 3-4. Am J Kidney Dis. 2014;64(3):367\u201374.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"483_CR45","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/ndt\/gfq397","volume":"26","author":"JJ Carrero","year":"2011","unstructured":"\u2022 Carrero JJ, Qureshi AR, Nakashima A, Arver S, Parini P, Lindholm B, et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant. 2011;26(1):184\u201390 Demonstrates the high prevalence of hypogonadism in men with CKD and potential impact on bone and muscle health.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"483_CR46","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.2215\/CJN.03600410","volume":"5","author":"O Gungor","year":"2010","unstructured":"Gungor O, Kircelli F, Carrero JJ, Asci G, Toz H, Tatar E, et al. Endogenous testosterone and mortality in male hemodialysis patients: is it the result of aging? Clin J Am Soc Nephrol. 2010;5(11):2018\u201323.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"483_CR47","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2215\/CJN.10681210","volume":"6","author":"MI Yilmaz","year":"2011","unstructured":"Yilmaz MI, Sonmez A, Qureshi AR, Saglam M, Stenvinkel P, Yaman H, et al. Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(7):1617\u201325.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"483_CR48","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1210\/edrv-6-2-151","volume":"6","author":"DJ Handelsman","year":"1985","unstructured":"Handelsman DJ. Hypothalamic-pituitary gonadal dysfunction in renal failure, dialysis and renal transplantation. Endocr Rev. 1985;6(2):151\u201382.","journal-title":"Endocr Rev"},{"issue":"3","key":"483_CR49","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/ki.1997.109","volume":"51","author":"L Dunkel","year":"1997","unstructured":"Dunkel L, Raivio T, Laine J, Holmberg C. Circulating luteinizing hormone receptor inhibitor(s) in boys with chronic renal failure. Kidney Int. 1997;51(3):777\u201384.","journal-title":"Kidney Int"},{"issue":"1\u20132","key":"483_CR50","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cccn.2004.11.017","volume":"354","author":"KD Schmidt","year":"2005","unstructured":"Schmidt KD, Valeri C, Leslie RD. Autoantibodies in type 1 diabetes. Clin Chim Acta. 2005;354(1\u20132):35\u201340.","journal-title":"Clin Chim Acta"},{"issue":"6","key":"483_CR51","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1210\/er.2004-0013","volume":"26","author":"JM Kaufman","year":"2005","unstructured":"Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005;26(6):833\u201376.","journal-title":"Endocr Rev"},{"issue":"3","key":"483_CR52","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1210\/jc.2005-1326","volume":"91","author":"V Kupelian","year":"2006","unstructured":"Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab. 2006;91(3):843\u201350.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"483_CR53","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1093\/ndt\/gfs383","volume":"27","author":"JJ Carrero","year":"2012","unstructured":"Carrero JJ, Stenvinkel P. The vulnerable man: impact of testosterone deficiency on the uraemic phenotype. Nephrol Dial Transplant. 2012;27(11):4030\u201341.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"483_CR54","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/ki.2014.425","volume":"87","author":"M Ketteler","year":"2015","unstructured":"Ketteler M, Elder GJ, Evenepoel P, Ix JH, Jamal SA, Lafage-Proust MH, et al. Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a kidney disease: improving global outcomes controversies conference. Kidney Int. 2015;87(3):502\u201328.","journal-title":"Kidney Int"},{"issue":"10","key":"483_CR55","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006\u201312.","journal-title":"J Clin Epidemiol"},{"key":"483_CR56","unstructured":"Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis (2011) [Available from: \n                      www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp\n                      \n                    ."},{"key":"483_CR57","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"2","key":"483_CR58","doi-asserted-by":"publisher","first-page":"464","DOI":"10.5812\/ijem.3794","volume":"10","author":"O Saito","year":"2012","unstructured":"Saito O, Saito T, Asakura S, Akimoto T, Inoue M, Ando Y, et al. Effects of raloxifene on bone metabolism in hemodialysis patients with type 2 diabetes. International Journal of Endocrinology and Metabolism. 2012;10(2):464\u20139.","journal-title":"International Journal of Endocrinology and Metabolism"},{"issue":"1","key":"483_CR59","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s10157-010-0366-0","volume":"15","author":"O Saito","year":"2011","unstructured":"Saito O, Saito T, Asakura S, Sugase T, Ito C, Ando Y, et al. The effects of raloxifene on bone turnover markers and bone mineral density in women on maintenance hemodialysis. Clin Exp Nephrol. 2011;15(1):126\u201331.","journal-title":"Clin Exp Nephrol"},{"issue":"7","key":"483_CR60","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1681\/ASN.2007050555","volume":"19","author":"A Ishani","year":"2008","unstructured":"Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol. 2008;19(7):1430\u20138.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"483_CR61","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3109\/13697137.2013.830605","volume":"17","author":"S Adami","year":"2014","unstructured":"Adami S, Palacios S, Rizzoli R, Levine AB, Sutradhar S, Chines AA. The efficacy and safety of bazedoxifene in postmenopausal women by baseline kidney function status. Climacteric. 2014;17(3):273\u201384.","journal-title":"Climacteric"},{"key":"483_CR62","unstructured":"J\u00f8rgensen HS, Winther S, B\u00f8ttcher M, Hauge EM, Rejnmark L, Svensson M, et al. Bioavailable testosterone is positively associated with bone mineral density in male kidney transplantation candidates. Kidney Int Report"},{"issue":"1","key":"483_CR63","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/j.1542-4758.2008.00249.x","volume":"12","author":"KK Doumouchtsis","year":"2008","unstructured":"Doumouchtsis KK, Kostakis AI, Doumouchtsis SK, Grapsa EI, Passalidou IA, Tziamalis MP, et al. The effect of sexual hormone abnormalities on proximal femur bone mineral density in hemodialysis patients and the possible role of RANKL. Hemodial Int. 2008;12(1):100\u20137.","journal-title":"Hemodial Int"},{"key":"483_CR64","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11657-012-0110-3","volume":"7","author":"S Mirfakhraee","year":"2012","unstructured":"Mirfakhraee S, Sakhaee K, Zerwekh J, Adams-Huet B, Gruntmanis U. Risk factors for diminished bone mineral density among male hemodialysis patients--a cross-sectional study. Arch Osteoporos. 2012;7:283\u201390.","journal-title":"Arch Osteoporos"},{"issue":"5","key":"483_CR65","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s00198-010-1350-y","volume":"22","author":"N Sugiya","year":"2011","unstructured":"Sugiya N, Nakashima A, Takasugi N, Kawai A, Kiribayashi K, Tanaka J, et al. Endogenous estrogen may prevent bone loss in postmenopausal hemodialysis patients throughout life. Osteoporos Int. 2011;22(5):1573\u20139.","journal-title":"Osteoporos Int"},{"issue":"2","key":"483_CR66","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1053\/j.ajkd.2005.10.022","volume":"47","author":"AT Brockenbrough","year":"2006","unstructured":"Brockenbrough AT, Dittrich MO, Page ST, Smith T, Stivelman JC, Bremner WJ. Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease. Am J Kidney Dis. 2006;47(2):251\u201362.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"483_CR67","first-page":"461","volume":"8","author":"F Haghverdi","year":"2014","unstructured":"Haghverdi F, Mortaji S, Soltani P, Saidi N, Farbodara T. Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5. Iranian Journal of Kidney Diseases. 2014;8(6):461\u20136.","journal-title":"Iranian Journal of Kidney Diseases"},{"issue":"5","key":"483_CR68","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1093\/ndt\/14.5.1238","volume":"14","author":"J Matuszkiewicz-Rowinska","year":"1999","unstructured":"Matuszkiewicz-Rowinska J, Skorzewska K, Radowicki S, Sokalski A, Przedlacki J, Niemczyk S, et al. The benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis. Nephrol Dial Transplant. 1999;14(5):1238\u201343.","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"483_CR69","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1744-9987.2011.00929.x","volume":"15","author":"M Tanaka","year":"2011","unstructured":"Tanaka M, Itoh K, Matsushita K, Matsushita K, Moriishi M, Kawanishi H, et al. Effects of raloxifene on bone mineral metabolism in postmenopausal Japanese women on hemodialysis. Ther Apher Dial. 2011;15(Suppl 1):62\u20136.","journal-title":"Ther Apher Dial"},{"issue":"5","key":"483_CR70","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/08860220500198698","volume":"27","author":"A Crisafulli","year":"2005","unstructured":"Crisafulli A, Romeo A, Floccari F, Aloisi E, Atteritano M, Cincotta M, et al. Osteoprotegerin and bone mineral density in hemodiafiltration patients. Ren Fail. 2005;27(5):531\u20139.","journal-title":"Ren Fail"},{"issue":"1","key":"483_CR71","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1046\/j.1523-1755.2000.00170.x","volume":"58","author":"JR Weisinger","year":"2000","unstructured":"Weisinger JR, Gonzalez L, Alvarez H, Hernandez E, Carlini RG, Capriles F, et al. Role of persistent amenorrhea in bone mineral metabolism of young hemodialyzed women. Kidney Int. 2000;58(1):331\u20135.","journal-title":"Kidney Int"},{"issue":"1","key":"483_CR72","doi-asserted-by":"publisher","first-page":"90","DOI":"10.2215\/CJN.03520414","volume":"10","author":"A Ishani","year":"2015","unstructured":"Ishani A, Liu J, Wetmore JB, Lowe KA, Do T, Bradbury BD, et al. Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol. 2015;10(1):90\u20137.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"483_CR73","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637\u201345.","journal-title":"JAMA"},{"issue":"5","key":"483_CR74","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1210\/jc.2017-00131","volume":"102","author":"CM Gordon","year":"2017","unstructured":"Gordon CM, Ackerman KE, Berga SL, Kaplan JR, Mastorakos G, Misra M, et al. Functional hypothalamic amenorrhea: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(5):1413\u201339.","journal-title":"J Clin Endocrinol Metab"},{"key":"483_CR75","doi-asserted-by":"crossref","unstructured":"The 2017 hormone therapy position statement of the North American Menopause Society. Menopause (New York, NY). 2017;24(7):728\u201353.","DOI":"10.1097\/GME.0000000000000921"},{"issue":"3","key":"483_CR76","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/gme.0b013e31804c793d","volume":"14","author":"JC Gallagher","year":"2007","unstructured":"Gallagher JC. Effect of early menopause on bone mineral density and fractures. Menopause (New York, NY). 2007;14(3):567\u201371.","journal-title":"Menopause (New York, NY)"},{"issue":"6","key":"483_CR77","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/j.1365-2265.1995.tb00544.x","volume":"43","author":"MC Davies","year":"1995","unstructured":"Davies MC, Gulekli B, Jacobs HS. Osteoporosis in Turner\u2019s syndrome and other forms of primary amenorrhoea. Clin Endocrinol. 1995;43(6):741\u20136.","journal-title":"Clin Endocrinol"},{"key":"483_CR78","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1471-2369-15-47","volume":"15","author":"A Parikh","year":"2014","unstructured":"Parikh A, Chase HS, Vernocchi L, Stern L. Vitamin D resistance in chronic kidney disease (CKD). BMC Nephrol. 2014;15:47.","journal-title":"BMC Nephrol"},{"key":"483_CR79","unstructured":"Bover FLAJ. Renal osteodystrophies. In: (Ed) BMB, editor. The kidney, 6th Edition. Philidelphia: W.B. Saunders; 2000. p. 2103\u201386."},{"issue":"21","key":"483_CR80","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1056\/NEJMra053077","volume":"354","author":"E Seeman","year":"2006","unstructured":"Seeman E, Delmas PD. Bone quality--the material and structural basis of bone strength and fragility. N Engl J Med. 2006;354(21):2250\u201361.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"483_CR81","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000045704","volume":"85","author":"TB Drueke","year":"2000","unstructured":"Drueke TB. Aspects of cardiovascular burden in pre-dialysis patients. Nephron. 2000;85(Suppl 1):9\u201314.","journal-title":"Nephron"},{"issue":"2","key":"483_CR82","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1681\/ASN.2004030203","volume":"16","author":"RN Foley","year":"2005","unstructured":"Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16(2):489\u201395.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"483_CR83","doi-asserted-by":"publisher","first-page":"e85805","DOI":"10.1371\/journal.pone.0085805","volume":"9","author":"WD Finkle","year":"2014","unstructured":"Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805.","journal-title":"PLoS One"},{"issue":"17","key":"483_CR84","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1001\/jama.2013.280386","volume":"310","author":"R Vigen","year":"2013","unstructured":"Vigen R, O'Donnell CI, Baron AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829\u201336.","journal-title":"JAMA"},{"issue":"6","key":"483_CR85","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.jsxm.2018.04.641","volume":"15","author":"G Corona","year":"2018","unstructured":"Corona G, Rastrelli G, Di Pasquale G, Sforza A, Mannucci E, Maggi M. Testosterone and cardiovascular risk: meta-analysis of interventional studies. J Sex Med. 2018;15(6):820\u201338.","journal-title":"J Sex Med"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-018-0483-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-018-0483-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-018-0483-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T19:07:04Z","timestamp":1571252824000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-018-0483-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,17]]},"references-count":85,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["483"],"URL":"https:\/\/doi.org\/10.1007\/s11914-018-0483-3","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,17]]},"assertion":[{"value":"17 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Peter Ebeling reports research grants and personal fees as a speaker from Eli-Lilly outside the submitted work. Jasna Aleksova, Alexander J. Rodriguez, Robert McLachlan, Peter Kerr and Frances Milat declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}